Dr. Olga Kubassova, CEO and Prof. Mikael Boesen of IAG will speak at IWOAI.
The CEO of IAG, Dr. Olga Kubassova, will be speaking during a panel discussion on the topic of “The ‘open data’ paradigm” and Prof. Mikael Boesen, IAG’s Head of Musculoskeletal Imaging Research will be chairing a session at the International Workshop on Osteoarthritis Imaging (IWOAI), July 2-5, 2021.
Dr. Kubassova’s talk, which will be on the 2nd July, is based on the fact that various stakeholders urge researchers and research institutions to openly share their study data as much as possible. In theory, most researchers and research institutions are willing to share their data, but in practice there are many barriers in openly sharing data. In reality, the majority of study data is not being shared.
The talk will address what the challenges are for industry partners to comply to the call for ‘open data’, how industry manages request for data sharing, and what solutions are available for data sharing by industry partners.
The International Workshop on Osteoarthritis Imaging started in 2007. It provides an interactive environment for those interested in osteoarthritis imaging to learn and network. Participants represent the diverse scope of the field and include professionals from specialties including medicine, surgery, radiology, medical physics and physiotherapists, as well as a broad array of professional backgrounds including academia, industry, government and regulatory agencies.
Imaging is critical in both the diagnosis and management of osteoarthritis. Clinical and epidemiological studies characteristically utilize imaging-derived inclusion/exclusion criteria as well imaging based outcome measures. This Workshop was established to offer opportunities for osteoarthritis investigators to discuss issues related to imaging of osteoarthritis. The topics of discussion may include new lessons learned about osteoarthritis pathophysiology by using imaging modalities, recent advances in imaging techniques and appropriate analytic methods of imaging derived data.
About Olga Kubassova
Dr. Olga Kubassova is a mathematician by background with MS in Mathematics from St. Petersburg State University, Russia, MS in Information Technology from Lappeenranta University of Technology, Finland and a PhD in Computer Science from the University of Leeds, UK. Dr. Olga Kubassova is the founding scientist and CEO of IAG, Image Analysis Group, an imaging expert company and a recognized partner to many blue-chip pharma companies in rheumatology, oncology and neurology. Olga is an active researcher, scientific adviser to the UK government and EU funding bodies, inc. European Commission, Innovative Medicines Initiative; she is an editor and reviewer of several scientific journals. Olga is a renowned healthcare innovator and biotech investor, with passion for improving people’s health.
About Mikael Boesen, MD, PhD
Head of Musculoskeletal Research at IAG, professor of radiology with focus on musculoskeletal imaging and head of the musculoskeletal imaging and research at Copenhagen University and Bispebjerg and Frederiksberg Hospital in the Capital region of Denmark. He has 20 years hands-on international experience in clinical research in inflammatory and degenerative joint diseases and serves as a global PI on trials. He is an author of 130+ articles, 6 book chapters and 160 abstracts and he has served as supervisor of more than 20 PhD students and postdocs.
About IAG, Image Analysis Group
Our goal is to accelerate novel drug development by using the right analytical tools and modern trial infrastructure. We take a broader view on the assets’ development and bring expertise in study design, execution, and commercialization. As needed, we deploy AI, Machine Learning, and smart image analysis methods to ensure the speed and cost-effectiveness of clinical programs. IAG’s team supports investors and biotech executive teams with deploying the right strategies for early efficacy assessments, objective response prediction and critical analysis of advanced treatment manifestations. Thus, lowering the investment risks into advanced therapies while helping to accelerate study outcomes. https://www.ia-grp.com